Protection against group A streptococcus by immunization with J8-diphtheria toxoid: contribution of J8- and diphtheria toxoid-specific antibodies to protection.
about
Accelerating the development of a group A Streptococcus vaccine: an urgent public health needStrategies in the development of vaccines to prevent infections with group A streptococcusCorrelates of Protection for M Protein-Based Vaccines against Group A StreptococcusBactericidal activity of M protein conserved region antibodies against group A streptococcal isolates from the Northern Thai population.Mechanism of protection induced by group A Streptococcus vaccine candidate J8-DT: contribution of B and T-cells towards protection.Local Th17/IgA immunity correlate with protection against intranasal infection with Streptococcus pyogenes.Correlation between bioluminescence and bacterial burden in passively protected mice challenged with a recombinant bioluminescent M49 group A streptococcus Strain.Protective efficacy of group A streptococcal vaccines containing type-specific and conserved M protein epitopes.Progress in the development of effective vaccines to prevent selected gram-positive bacterial infections.Immunological evaluation of lipopeptide group A streptococcus (GAS) vaccine: structure-activity relationshipemm gene diversity, superantigen gene profiles and presence of SlaA among clinical isolates of group A, C and G streptococci from western Norway.Disease manifestations and pathogenic mechanisms of Group A Streptococcus.Lipid core peptide technology and group A streptococcal vaccine delivery.Streptococcus pyogenes strains in Sao Paulo, Brazil: molecular characterization as a basis for StreptInCor coverage capacity analysisPredicted Coverage and Immuno-Safety of a Recombinant C-Repeat Region Based Streptococcus pyogenes Vaccine Candidate.Immunogenicity and efficacy of Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan peptide mimotope-protein conjugates in human immunoglobulin transgenic mice.Prospects for a group A streptococcal vaccine: rationale, feasibility, and obstacles--report of a National Institute of Allergy and Infectious Diseases workshop.Immunization with a streptococcal multiple-epitope recombinant protein protects mice against invasive group A streptococcal infectionIn vivo efficacy of a chimeric peptide derived from the conserved region of the M protein against group C and G streptococciLong-term antibody memory induced by synthetic peptide vaccination is protective against Streptococcus pyogenes infection and is independent of memory T cell help.Therapeutic efficacy of a conjugate vaccine containing a peptide mimotope of cryptococcal capsular polysaccharide glucuronoxylomannanDiffering Efficacies of Lead Group A Streptococcal Vaccine Candidates and Full-Length M Protein in Cutaneous and Invasive Disease Modelsemm and C-repeat region molecular typing of beta-hemolytic Streptococci in a tropical country: implications for vaccine developmentNovel strategies for controlling Streptococcus pyogenes infection and associated diseases: from potential peptide vaccines to antibody immunotherapy.Immunogenicity in mice and non-human primates of the Group A Streptococcal J8 peptide vaccine candidate conjugated to CRM197.Moving forward: a mucosal vaccine against group A streptococcus.Novel platform technology for modular mucosal vaccine that protects against streptococcus.Prevention and treatment of rheumatic heart disease in the developing world.Intranasal vaccination with streptococcal fibronectin binding protein Sfb1 fails to prevent growth and dissemination of Streptococcus pyogenes in a murine skin infection model.Cutting edge issues in rheumatic fever.Vaccination against rheumatic heart disease: a review of current research strategies and challenges.Diagnosis and treatment of invasive group A streptococcal infections.Strategic development of the conserved region of the M protein and other candidates as vaccines to prevent infection with group A streptococci.Development of Group A streptococcal vaccines: an unmet global health need.Preclinical immunogenicity and safety of a Group A streptococcal M protein-based vaccine candidate.Peptide-based synthetic vaccines.A systematic and functional classification of Streptococcus pyogenes that serves as a new tool for molecular typing and vaccine development.Serum opacity factor (SOF) of Streptococcus pyogenes evokes antibodies that opsonize homologous and heterologous SOF-positive serotypes of group A streptococci.Combinatorial Synthetic Peptide Vaccine Strategy Protects against Hypervirulent CovR/S Mutant Streptococci.Enhancing Vaccine Efficacy by Engineering a Complex Synthetic Peptide To Become a Super Immunogen.
P2860
Q26739210-873A67F4-009A-44AA-849A-14D0EF0F1FEAQ26863366-788DD8E3-10DA-40E4-932A-38FA26B6C207Q27009175-F0B4FEB3-BAB9-490A-AA70-ABCF83FD81AEQ33253260-0638A9F3-CF59-46D8-B82C-D3D97D2BAEC3Q33425912-A515D965-3623-49A0-839A-45B68CDAA77BQ33570612-C11371CE-EE7F-4271-9FBA-F28C1DE32852Q33613541-FFE7CC5C-264F-42AB-986A-6283DFF571E9Q34005434-F9AC9237-5330-47D3-AD0B-A254F8EA9575Q34112608-28A39967-8D8F-4D31-B1FF-D4E5E3FF59EDQ34131142-791F126F-A70D-46D1-B123-6F68BFA8C959Q34151601-8569D50D-4C41-49DC-92C8-8D2F68C027F7Q34413457-DD5AF624-94FC-4462-8B01-F526FE8F64DFQ35648250-435CF1D0-EAD1-46E4-A9FD-9612A480A097Q35737965-871FC887-6BC2-4567-BDC1-AC496B5D69CBQ36054412-14A4C1E2-DDDD-483E-96D6-485CEBEB175BQ36228216-C949A85E-5725-49F6-ADA3-21590A58CA08Q36257688-A711247C-0AC5-4E08-B9AA-AB544A5AB6DCQ36326757-6B20ACAE-5368-4422-9695-580806B65594Q36505180-5B47323A-19CF-4BA7-98B8-52508A487E19Q36675649-1AA5B0B7-6DCB-47DB-A5BF-571E71A4121BQ36844895-0AA9921D-F86B-46AF-B2F1-3191D8CBD49FQ37027300-2BC2C36D-07F4-48D7-99FA-D5E4025ED340Q37302090-320EFCA7-8BB4-4C90-88A5-BEAC1F3991CAQ37471470-7B954EB7-6B5F-490C-8A75-329F6B83BED1Q37478261-1CFD72BA-D8CE-456E-B666-DA0CC838FB1CQ37503248-13677B07-C820-45B0-8D1F-9E040113C37FQ37504796-53A623D3-C31C-411E-ACDB-8CE96A3BADA3Q37596966-CB32885B-475A-4A68-904E-B6D45D845077Q37623644-C42DDD7B-D7CB-4D64-8C29-99E8923BAD0DQ37877594-17991F91-4EE4-4002-AA76-A40D018DC238Q38021366-FDC63201-0B5F-4617-BE02-D02CE052DC63Q38089734-C3F15707-5B16-44A8-BEFA-CE1CBB4958F2Q38612165-10791BEA-221F-4A05-8712-DA20DF0ACEA2Q38631048-65ECFC6B-AC94-4664-BFF5-9C42AE070522Q38897169-DC724854-717D-4A74-8EF6-DAFB1218B86EQ38914295-109DC323-6933-4FFD-8E10-6E608951BA2BQ39197885-7CC2678A-4276-4FB9-9E81-6EC49A022835Q39863755-23A72103-EEA2-4040-B2C6-FE166BBF709EQ39926669-FD0F5B08-33DA-4AB9-887C-5F454990989FQ40048109-A8817AAA-55CC-49E8-A550-B7784DD9EAA0
P2860
Protection against group A streptococcus by immunization with J8-diphtheria toxoid: contribution of J8- and diphtheria toxoid-specific antibodies to protection.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Protection against group A str ...... ific antibodies to protection.
@en
type
label
Protection against group A str ...... ific antibodies to protection.
@en
prefLabel
Protection against group A str ...... ific antibodies to protection.
@en
P2093
P356
P1476
Protection against group A str ...... ific antibodies to protection.
@en
P2093
Evelyn R Brandt
Michael F Good
Michael R Batzloff
Sumalee Pruksakorn
Wendy A Hayman
P304
P356
10.1086/374800
P407
P577
2003-04-30T00:00:00Z